Results 281 to 289 of about 43,902 (289)

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

Lancet Oncology, The, 2010
David M Thomas,,, Fracp, Keith M Skubitz, J-Y Blay   +2 more
exaly  

Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

Cell Metabolism, 2015
Adolfo Garcia-Ocaña
exaly  

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

Journal of Clinical Oncology, 2008
Rowan T Chlebowski
exaly  

Denosumab an option for patients with bone metastasis from breast cancer

Ca-A Cancer Journal for Clinicians, 2011
exaly  

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS

Bone, 2017
Elena Tsourdi, Bente Lomholt Langdahl, Martine Cohen Solal   +2 more
exaly  

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Nature Reviews Drug Discovery, 2012
exaly  

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Lancet Diabetes and Endocrinology,the, 2018
Kenneth G Saag, Piet Geusens, Jonathan D Adachi   +2 more
exaly  

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2019
Michael Fx Gnant, Richard F Greil, Florian Fitzal   +2 more
exaly  

Managing bone metastases and reducing skeletal related events in prostate cancer

Nature Reviews Clinical Oncology, 2014
Fred Saad
exaly